^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/10/2021
Excerpt:
IDAMYCIN (idarubicin hydrochloride for injection, USP) in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American- British (FAB) classifications M1 through M7.
